Author

Andreas Unterberg

Heidelberg University

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1 Assay:proteomics· 1

Frequent Co-Authors

Christel C. Herold‐MendeiD· 2 shared Albrecht StenzingeriD· 1 shared Alexander YounsiiD· 1 shared Amir AbdollahiiD· 1 shared Amirhossein SakhtemaniD· 1 shared Andreas SchneeweißiD· 1 shared Andreas von DeimlingiD· 1 shared Annika SchneideriD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Christel C. Herold‐MendeORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Prospective pan-cancer phosphoproteomics at clinical scale extends therapeutic options in precision oncology

Annika Schneider, Julia Wortmann, Cecilia Bang Jensen, Leonardo Estrada Duenas, Maria‐Veronica Teleanu, Amirhossein Sakhteman, Firas Hamood, Florian P Bayer, Christoph Stange, Jeremiah Bintang Santoso, Jennifer Hüellein, Nindo B. Punturi, Lee Dolat, Peter Horak, Resch Moritz, , Bernhard Küster

This study uses pan-cancer phosphoproteomics to identify therapeutic targets and improve precision oncology by analyzing 1,998 tumor samples and developing new scores for kinase activity and immune response.

bioRxiv · Jul 9, 2026 · PreprintCancer Biology

Personalized Medicine for Meningiomas: Drug Screening on Tumor Organoids Exposes Therapeutic Vulnerabilities to HDAC1/2i Panobinostat

Gerhard Jungwirth, Junguo Cao, Yimin Pan, Rolf Warta, Catharina Lotsch, Mahmoud Moustafa, Maximilian Knoll, Tao Yu, Viktor Braun, Lena Jassowicz, Philip Dao Trong, Zhenlin Wang, Alexander Younsi, Moritz Scherer, M. Bendszus, , Christel C. Herold‐Mende

This study identifies panobinostat as an effective treatment for aggressive meningiomas through drug screening on tumor organoids and reveals a resistance mechanism involving the HDAC8-TGFβ-EMT axis.

Science Translational Medicine · Mar 4, 2026Peer-reviewedCancer Biology